Kemin Industries acquires Amalyte Pharmaceuticals

DES MOINES, Iowa A food, pet food and pharmaceutical products company has acquired a drug maker based in the San Francisco Bay area to expand its pharmaceutical business.

Kemin Industries announced this week the acquisition of Atherton, Calif.-based Amalyte Pharmaceuticals, saying it would help to develop Amalyte’s product pipeline and expand its clinical and preclinical capabilities in Europe and Asia. Amalyte is focused on identifying and developing treatments for immune and inflammatory diseases.

“Amalyte was looking for a strategic partner to provide financing, expertise and capability to help it advance its clinical stage programs,” Amalyte VP business development David Nelson said. “In Kemin, we found all of those things in one package.”